Akoya Biosciences (NASDAQ:AKYA) Earns Overweight Rating from Piper Sandler

Piper Sandler reissued their overweight rating on shares of Akoya Biosciences (NASDAQ:AKYA) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $3.00 target price on the stock, down from their previous target price of $4.00.

Several other equities research analysts have also recently issued reports on AKYA. BTIG Research cut shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Canaccord Genuity Group dropped their target price on shares of Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, November 15th. JPMorgan Chase & Co. cut shares of Akoya Biosciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, August 6th. Morgan Stanley cut shares of Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $4.00 to $3.00 in a report on Tuesday, August 6th. Finally, Craig Hallum cut shares of Akoya Biosciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $7.00 to $5.00 in a report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Akoya Biosciences currently has an average rating of “Hold” and an average target price of $5.43.

Akoya Biosciences Trading Down 0.5 %

Shares of AKYA stock opened at $2.11 on Tuesday. Akoya Biosciences has a 12-month low of $1.88 and a 12-month high of $6.31. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. The firm’s 50 day moving average is $2.85 and its 200 day moving average is $2.58. The stock has a market capitalization of $104.57 million, a P/E ratio of -1.79 and a beta of 1.34.

Institutional Trading of Akoya Biosciences

Several institutional investors and hedge funds have recently modified their holdings of AKYA. Regal Investment Advisors LLC raised its position in shares of Akoya Biosciences by 64.3% during the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after purchasing an additional 7,340 shares during the period. Barclays PLC raised its position in shares of Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock valued at $107,000 after purchasing an additional 30,095 shares during the period. Bank of New York Mellon Corp raised its position in shares of Akoya Biosciences by 16.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares during the period. GSA Capital Partners LLP raised its position in shares of Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after purchasing an additional 144,903 shares during the period. Finally, State Street Corp raised its position in shares of Akoya Biosciences by 4.2% during the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after purchasing an additional 18,361 shares during the period. 79.42% of the stock is currently owned by institutional investors.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.